Dr. Frances Shepherd CV - (NCRI) is

131. Horgan AM, Yang B, Azad AK, Amir E, John T, Cescon DW, Wheatley-Price P, Hung
RJ, Shepherd FA, Liu G. Pharmacogenetic and germline prognostic markers of lung
cancer. J Thorac Oncol. 2011; 6: 296-304.
132. Tsao Ms, Sakurada A, Ding K, Aviel-Ronen S, Ludkovski O, Liu N, Le Maitre A,
Gandara D, Johnson DH, Rigas JR, Seymour L, Shepherd FA. Prognostic and
predictive value of epidermal growth factor receptor tyrosine kinase domain mutuation
status and gene copy number for adjuvant chemotherapy in non-small cell lung cancer.
J Thorac Oncol. 2011; 6: 139-47.
133. Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, van Seenkiste J, et al. Treatment
by histology interaction analyses in three phase III trails show superiority of pemetrexed
in non-squamous non-small cell lung cacner. J Thorac Oncol 2011; 6: 64-70.
134. Reiman T, Lai R, Veillard AS, Psaris E. Sora JC, Rosell R, Taron M, Graziano S,
Kratzke R, Seymour L, Shepherd FA, Pignon JP, Seve P for the LACE-Bio Group.
Cross-validation study of class III beta-tubulin as a predictive marker for benefit from
adjuvant chemotherapy in resected non-small cell lung cancer: analysis of four
randomized trials. Ann Oncol. 2012; 23: 86-93.
135. Brade A, Bezjak A, MacRae R, Laurie S, Sun A, Cho J, Leighl N, Pearson S,
Southwood B, Wang L, Mcgill S, Iscoe N, Shepherd FA. Phase I trial of radiation with
concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage
III/a/B non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011; 79: 1395-40.
136. Navaratnum S, Skliris G, Qing G, Banerji S, Badiani K, Bradbury PA, Leighl NB,
Shepherd FA, et al. Differential role of estrogen receptor beta in early versus metastatic
non-small cell lung cancer. Horm Cancer 2012;
137. Giuliani ME, Lindsay PE, Sun A, Bezjak A, Le LW, Brade A, Cho J, Leighl NB,
Shepherd FA, Hope AJ. Locoregional failures following thoracic irrradiation in patients
with limited stage small-cell lung cancer. Radiother Oncol 2102;
138. Liu G, Cheng D, Ding K, Le Maitre A, Liu N, Patel D, Chen Z, Seymour L, Shepherd
FA, Tsao MS. Pharmacogenetic analysis of BR.21, a placebo-controlled randomized
Phase III clinical trial of erlotinib in advanced non-small cell lung cancer. J Thorac
Oncol 2012;
12. BOOK CHAPTERS LAST 5 YEARS OUT OF A TOTAL OF 44
1. Leighl N and Shepherd FA. Adjuvant chemotherapy for non-small cell lung cancer. In:
General Thoracic Surgery Seventh Edition: Shields TW, Locicero III J, Feins R (eds).
Lipincott Williams & Wilkins, Philadelphia 2008 In Press.
2. Ellis P and Shepherd FA. Second-line chemotherapy for non-small cell lung cancer. In:
Lung Cancer: Principles and Practice 4th Edition: Pass H, Mitchell J, Johnson D, Turrisi
D (eds). JB Lippincott, Philadelphia, 2008 In Press.
3. Leighl NB, Shepherd FA. Small Cell Lung Cancer. Pearson’s Thoracic & Esophageal
Surgery Third Edition Volume 1 Thoracic: Churchill Livingston Elsevier, 825 – 840,
2008.
4. Leighl NB, Shepherd FA. Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer.
General Thoracic Surgery Seventh Edition Volume 1 Lippincott Williams & Wilkins,
2009
5. Wheatley-Price P and Shepherd FA. Epidermal Growth Factor Receptor Inhibitors in the
Treatment of Non-Small Cell Lung Cancer. Humana Press. Stewart D Ed 2010; 205-226.
6. Wheatley-Price P, Shepherd FA. Lung Cancer Prevention, Management, and Emerging
Therapies. Humana Press 2010.
15